A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Inclusion Criteria:

ECOG PS of 0 or 1
Histologically confirmed NSCLC
Adequate amount of tumor (archived or fresh) for biomarker evaluation
Received one to two regimens of chemotherapy (with at least one platinum-containing)
Serum creatinine of less than 1.0 mg/dL or a 24 hour creatinine clearance of greater than 60 mL/min
Stable control of blood pressure on agents other than calcium channel blockers
Women of child-bearing potential must avoid pregnancy or maintain adequate contraception
Must be able to swallow pills and take the medications at the same time every day on an empty stomach

Exclusion Criteria:

ECOG PS 2 or greater
Women unwilling to avoid pregnancy or use adequate contraception
Symptomatic brain metastases
Recent history of TIA, CVA, or thrombotic/thromboembolic event (within 6 months)
History of hemoptysis greater than 10 mL/day
Significant cardiovascular disease
Uncontrolled diarrhea, Crohn's disease, ulcerative colitis, or any malabsorptive disease
History of use of other TKIs
Uncontrolled hypertension
HIV+